Holtkamp 2002.

Methods	A patient report of growth impairment during methylphenidate treatment
Participants	Diagnosis of ADHD: DSM‐IV (subtype: not stated) Age: 7.6 years old IQ: normal Sex: male Ethnicity: not stated Country: Germany Comorbidity: bronchial asthma Comedication: inhaled corticosteroids Sociodemographics: not stated
Interventions	Methylphenidate type: not stated Methylphenidate dosage: 0.75‐0.8 mg/kg/day Administration schedule: morning and noon Duration of treatment: 19 months Treatment compliance: not stated
Outcomes	Non‐serious adverse events: Appetite loss (only in the first weeks of medicine) Growth impairment
Notes	Funding/vested interests: not stated Key conclusions of the study authors: one may conclude that some children are at risk of serious growth decrement when treated with methylphenidate. The growth of children should thus be monitored carefully, even if there are no alarming gastrointestinal side effects from methylphenidate. We found that the determination of growth velocity was a sensitive marker for the evaluation of growth impairment in our patient